A recent phase II trial has analyzed the combination of anti-CTLA4 tremelimumab plus anti-PDL1 durvalumab in 57 patients with advanced STS and BS after at least one line of systemic treatment [91]. The gene discussed is CD274; the disease is telomere syndrome.